Active, not recruitingPHASE1, PHASE2NCT02726997
Matched Paired Pharmacodynamics and Feasibility Study of Durvalumab in Combination With Chemotherapy in Frontline Ovarian Cancer (N-Dur)
Studying Primary peritoneal tumor
Last synced from ClinicalTrials.gov
ℹ
Clinical trial records are synced from ClinicalTrials.gov through automated extraction.
Report missing dataKey facts
- Sponsor
- M.D. Anderson Cancer Center
- Principal Investigator
- Shannon N Westin, MDM.D. Anderson Cancer Center
- Intervention
- Carboplatin(drug)
- Enrollment
- 18 target
- Eligibility
- 18 years · FEMALE
- Timeline
- 2016 – 2027
Study locations (1)
- M D Anderson Cancer Center, Houston, Texas, United States
Collaborators
National Cancer Institute (NCI)
Primary source
Recruitment status, site addresses, contacts, and full eligibility criteria can change between syncs. Always verify with the trial team before planning travel or treatment.
Open NCT02726997 on ClinicalTrials.govOther trials for Primary peritoneal tumor
Additional recruiting or active studies for the same condition.
- RECRUITINGPHASE1, PHASE2NCT07589543Dual-Target CAR-NK Cells in Recurrent or Refractory Epithelial Ovarian CancerBeijing Biotech
- RECRUITINGPHASE2NCT07586826Romiplostim N01 Plus ATRA for Persistent Isolated Chemotherapy-Induced Thrombocytopenia After Complete Remission of Gynecologic, Breast, or Lung Solid TumorsPeking University People's Hospital
- ACTIVE NOT RECRUITINGNCT06483997Diet, Hepcidin, and Chemotherapy RDIGeorge Washington University